Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 13/20 | 0.51 |
| ▸ | IDH2 | P48735 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561107 | 1.00 | IDH1 (0.51) | IDH1IDH2POLBMAPK14L3MBTL1 | |
| SCHEMBL25989712 | 0.89 | IDH1 (0.45) | IDH1IDH2POLBMAPK14L3MBTL1 | |
| SCHEMBL29763331 | 0.87 | RHOA (0.56) | IDH1IDH2POLBNPC1RAB9A | |
| SCHEMBL15094676 | 0.87 | RHOA (0.56) | IDH1IDH2POLBNPC1RAB9A | |
| SCHEMBL15094853 | 0.83 | KCNH3 (0.49) | IDH1IDH2POLBL3MBTL1NPC1 | |
| SCHEMBL20018006 | 0.78 | POLB (0.71) | IDH1IDH2POLB | |
| SCHEMBL29560995 | 0.78 | KCNH3 (0.66) | IDH1IDH2POLB | |
| SCHEMBL15102366 | 0.78 | KCNH3 (0.66) | IDH1IDH2POLB | |
| SCHEMBL29561084 | 0.76 | IDH1 (0.53) | IDH1IDH2POLB | |
| SCHEMBL15102285 | 0.76 | IDH1 (0.53) | IDH1IDH2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647076-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier (FR) | 2025-11-12 | — | — | EP | disclosed |
| EP-3984997-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER LAB (FR) | 2025-07-30 | — | — | EP | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | disclosed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-03 | — | — | US | disclosed |
| CN-114933585-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-08-23 | — | — | CN | disclosed |
| CN-108912066-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512107-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-11-03 | — | — | US | disclosed |
| EP-2800743-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348554-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885POLB 566/4885 |
| US-20160318903-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | IDH1 456/4885IDH2 203/4885POLB 582/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885POLB 566/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885POLB 566/4885 |
| US-20170044139-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885POLB 566/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885POLB 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.